Lyell Immunopharma, Inc.
LYEL Nasdaq
SEC CIK 1806952
Follow Lyell Immunopharma
Weekly email: filings, results
Revenue, last quarter
$3K
−80% vs same quarter last year
Net income
−$45.5M
−17.2% vs same quarter last year
EPS, diluted
−$1.86
+12.7% vs same quarter last year
Operating cash flow
−$34.6M
−21% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $36K | −$274.4M |
| FY24 | $61K | −$343M |
| FY23 | $130K | −$234.6M |
| FY22 | $84.7M | −$183.1M |
| FY21 | $10.7M | −$250.2M |
| FY20 | $7.8M | −$204.5M |
| FY19 | $657K | −$129.4M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −748344.4% | −762355.6% |
| FY24 | −588123% | −562285.2% |
| FY23 | −190006.2% | −180486.2% |
| FY22 | −220.9% | −216.2% |
| FY21 | −2016.7% | −2349.5% |
| FY20 | −2732.6% | −2636.3% |
| FY19 | −15538.7% | −19692.1% |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$150.8M |
| FY24 | −$162.9M |
| FY23 | −$166.4M |
| FY22 | −$193.8M |
| FY21 | −$191.8M |
| FY20 | −$212.4M |
| FY19 | $23.4M |
| FY18 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | $11.8M |
| FY19 | $185K |
| FY18 | - |
- Lyell Immunopharma
- Healthcare median
Show the numbers
| Year | Lyell Immunopharma | Healthcare median |
|---|---|---|
| FY25 | −762355.6% | −30.6% |
| FY24 | −562285.2% | −47% |
| FY23 | −180486.2% | −58% |
| FY22 | −216.2% | −80.4% |
| FY21 | −2349.5% | −71.8% |
| FY20 | −2636.3% | −62.2% |
| FY19 | −19692.1% | −46.2% |
| FY18 | - | −49.6% |